Abstract
The 2019 coronavirus (COVID-19) pandemic and associated lockdowns significantly disrupted healthcare systems, including access to pharmacological treatments such as sleep medication. This study investigated the number of first-time dispensed hypnotic drugs during the first COVID-19 lockdown in the Netherlands, using data from the Dutch Foundation for Pharmaceutical Statistics (SFK), which covers approximately 96% of all pharmacy dispensations (5.46 million patients). First-time dispensing was defined as no use of hypnotics in the previous year and included benzodiazepines, benzodiazepine-related drugs, and melatonin receptor agonists. Data from 2020 were analysed across three periods: pre-lockdown (Weeks 1-11), lockdown (Weeks 12-19) and post-lockdown (Weeks 20-26), and were compared to the same periods in 2019. Analyses were stratified by age group (children: 0-9, adolescents: 10-19, adults: 20-64, elderly: 65+) and sex. The data revealed a significant reduction in first-time hypnotic dispensations in 2020 (155,961) compared to 2019 (168,814, p < 0.001), with declines across all three time periods (p < 0.001). During the lockdown, significant reductions were found among children, adolescents, and adults (p < 0.001), but not among the elderly. Female adults and the elderly received significantly more hypnotics than their male counterparts (p < 0.001), consistent with higher reported rates of sleep disturbances. In conclusion, the overall number of first-time dispensed hypnotics was significantly lower during the first COVID-19 lockdown in the Netherlands, except among the elderly. It remains unclear to what extent individuals self-medicated with over-the-counter sleep medication, or experienced untreated sleep complaints during the first lockdown in the Netherlands.
| Original language | English |
|---|---|
| Article number | e70190 |
| Journal | Journal of Sleep Research |
| DOIs | |
| Publication status | E-pub ahead of print - 25 Aug 2025 |
Bibliographical note
Publisher Copyright:© 2025 The Author(s). Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.
Funding
Over the past 36 months, J.C.V. has received research grants from Danone and Inbiose and has acted as a consultant/expert advisor to Eisai, KNMP, Med Solutions, Mozand, Red Bull, Sen‐Jam Pharmaceutical, and Toast!. J.C.V., D.M.D. and M.N.Z. have received travel support from Sen‐Jam Pharmaceutical. J.C.V. owns stock from Sen‐Jam Pharmaceutical. J.G. is a part‐time employee of Nutricia Research and received research grants from Nutricia Research Foundation, Top Institute Pharma, Top Institute Food and Nutrition, GSK, STW, NWO, Friesland Campina, CCC, Raak‐Pro, and EU. P.K. is the CEO of Pangenix. P.A.H. has nothing to declare.
| Funders |
|---|
| Top Institute Pharma |
| Nutricia |
| European Commission |
| Nutricia Research Foundation |
| GlaxoSmithKline |
| Top Institute Food and Nutrition |
| Crohn's and Colitis Canada |
| STW |
| NWO |
| Friesland Campina |
Keywords
- COVID-19
- delayed healthcare
- hypnotic drugs
- lockdown
- prescriptions